Eisenhofer G
Clinical Neuroscience Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20892.
Neurochem Int. 1993 May;22(5):493-9. doi: 10.1016/0197-0186(93)90045-7.
Concentrations of noradrenaline at peripheral neuronal uptake sites were examined during sustained changes in sympathetic nervous activity produced by intracisternal infusion of yohimbine or clonidine in conscious rabbits. The gradient between concentrations of noradrenaline in plasma and at neuronal uptake sites was estimated by comparing the formation of the intraneuronal metabolite of noradrenaline, dihydroxyphenylglycol (DHPG), from intravenously infused and endogenously released noradrenaline. At resting levels of sympathetic activity the noradrenaline concentration at neuronal uptake sites (4.2 +/- 0.5 nmol/l) was 3.4-fold greater than the concentration in arterial plasma (1.3 +/- 0.1 nmol/l). Noradrenaline at neuronal uptake sites increased to 9.4 +/- 1.3 nmol/l after yohimbine and decreased to 2.4 +/- 0.1 nmol/l after clonidine. The noradrenaline concentration gradient was not altered by intracisternal infusion of yohimbine or clonidine. Thus, a positive linear relationship (r = 0.97) was observed between concentrations of noradrenaline at neuronal uptake sites and in plasma. The gradient was positively related to the efficiency of noradrenaline reuptake (r = 0.81). The results show that arterial plasma concentrations of noradrenaline are considerably less than concentrations close to sites of release, but accurately reflect changes in amounts of noradrenaline at release sites during sustained changes in sympathetic activity. The gradient in noradrenaline concentrations between neuronal uptake sites and plasma is largely dependent on the efficiency of neuronal reuptake. Since the gradient is not altered by sympathetic nervous inhibition or activation, the proportion of noradrenaline removed by neuronal and extraneuronal uptake does not appear to be altered by moderate changes in transmitter release.
在清醒兔中,通过脑池内注入育亨宾或可乐定引起交感神经活动持续变化期间,检测外周神经元摄取部位去甲肾上腺素的浓度。通过比较静脉注射和内源性释放的去甲肾上腺素生成的神经元内代谢产物二羟基苯乙二醇(DHPG),来估算血浆和神经元摄取部位去甲肾上腺素浓度之间的梯度。在交感神经活动的静息水平,神经元摄取部位的去甲肾上腺素浓度(4.2±0.5 nmol/L)比动脉血浆中的浓度(1.3±0.1 nmol/L)高3.4倍。育亨宾注射后,神经元摄取部位的去甲肾上腺素增加至9.4±1.3 nmol/L,可乐定注射后则降至2.4±0.1 nmol/L。脑池内注入育亨宾或可乐定不会改变去甲肾上腺素浓度梯度。因此,观察到神经元摄取部位和血浆中去甲肾上腺素浓度之间呈正线性关系(r = 0.97)。该梯度与去甲肾上腺素再摄取效率呈正相关(r = 0.81)。结果表明,动脉血浆中的去甲肾上腺素浓度远低于释放部位附近的浓度,但能准确反映交感神经活动持续变化期间释放部位去甲肾上腺素量的变化。神经元摄取部位和血浆之间去甲肾上腺素浓度的梯度很大程度上取决于神经元再摄取的效率。由于该梯度不会因交感神经抑制或激活而改变,因此,适度的递质释放变化似乎不会改变神经元和非神经元摄取去除的去甲肾上腺素比例。